Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Allyl Alcohol SCHEMBL28396167 | 0.85 | — | — | |
| Allyl Alcohol SCHEMBL4601219 | 0.84 | — | — | |
| Allyl Alcohol SCHEMBL4940557 | 0.80 | — | — | |
| Allyl Alcohol SCHEMBL3782 | 0.80 | — | — | |
| Allyl Alcohol SCHEMBL1331425 | 0.80 | — | — | |
| Allyl Alcohol SCHEMBL1332489 | 0.80 | — | — | |
| Allyl Alcohol SCHEMBL565195 | 0.76 | — | — | |
| Allyl Alcohol SCHEMBL4665160 | 0.76 | — | — | |
| Allyl Alcohol SCHEMBL4729230 | 0.76 | — | — | |
| Allyl Alcohol SCHEMBL5382706 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486004-B1 | SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | ZAFGEN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160051531-A1 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-02-25 | — | — | US | disclosed |
| US-9067905-B2 | Sulphone compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-02-28 | — | — | US | disclosed |
| EP-2486004-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen Corporation (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044506-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
| EP-0166697-B1 | AROYL SUBSTITUTED DIHYDRO-1,4-THIAZINES | CIBA-GEIGY AG (CH) | 1990-05-09 | — | — | EP | disclosed |
| EP-0166697-A2 | Aroyl substituted dihydro-1,4-thiazines | CIBA-GEIGY AG (CH) | 1986-01-02 | — | — | EP | disclosed |
| US-4213982-A | USE TO PROMOTE GROWTH RATE OR FEED EFFICIENCY IN LIVESTOCK | E. R. SQUIBB & SONS, INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4164498-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, TRANQUILIZERS, SEDATIVES, GROWTH PROMOTERS, ANTICONVULSANTS, MUSCLE RELAXANTS | E. R. SQUIBB & SONS, INC. (US) | 1979-08-14 | — | — | US | disclosed |
| US-4164580-A | 4H-s-Triazolo[4,3-a][1,5]benzodiazepin-5-ones as tranquilizers | E. R. SQUIBB & SONS, INC. (US) | 1979-08-14 | — | — | US | disclosed |
| US-4133809-A | DEPRESSANTS, TRANQUILIZERS, SEDATIVES, GROWTH PROMOTERS, ANTICONVULSANTS, MUSCLE RELAXANTS | E. R. SQUIBB & SONS, INC. (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051531-A1 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, DNPEP, STS | TSHR 3569/4885 |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | METAP2, DNPEP, STS | TSHR 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.